Eli Lilly and Co
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis
- First Posted Date
- 2013-06-24
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 2877
- Registration Number
- NCT01885078
- Locations
- π¬π·
Hippokration Hospital of Athens, Athens, Attiki, Greece
π¬π·University General Hospital of Larissa, Larissa, Greece
πΊπΈDiagnostic Rheumatology and Research, Indianapolis, Indiana, United States
A Study of LY2605541 in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: LY2605541
- First Posted Date
- 2013-06-13
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT01877265
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
A Study of LY2875358 in Participants With MET Positive, Advanced Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- Biological: LY2875358
- First Posted Date
- 2013-06-11
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 15
- Registration Number
- NCT01874938
- Locations
- π°π·
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of
A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 124
- Registration Number
- NCT01872910
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States
A Study of LY3025876 in Participants With Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 72
- Registration Number
- NCT01870297
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, United States
Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)
- Conditions
- Spondylitis, Ankylosing
- Interventions
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2014-09-16
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT01870284
- Locations
- π¬π§
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT01870388
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States
A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2014-10-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT01871493
- Locations
- πΈπ¬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore
A Study of LY2405319 in Participants With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: LY2405319Drug: Placebo
- First Posted Date
- 2013-06-05
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 47
- Registration Number
- NCT01869959
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States
A Study of Multiple Doses of LY2922470 in Participants With Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: PlaceboDrug: LY2922470
- First Posted Date
- 2013-06-03
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 66
- Registration Number
- NCT01867216
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States